Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.

Autor: Saukkonen, Kapo^1,2 kapo.saukkonen@helsinki.fi, Hagström, Jaana^2,3, Mustonen, Harri¹, Juuti, Anne¹, Nordling, Stig³, Kallio, Pauliina², Alitalo, Kari², Seppãnen, Hanna¹, Haglund, Caj^1,2, Seppänen, Hanna⁴ (AUTHOR)

Publikováno v: BMC Cancer. 7/13/2016, Vol. 16, p1-12. 12p. 4 Color Photographs, 6 Charts, 3 Graphs.

Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma

Autor: Saukkonen, Kapo

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Radical surgical resection combined with chemotherapy, the only potentially curative treatment, is possible in only a small proportion of patients. Although overall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1593::34cd043073cf94698a14b753c2ca4355
http://hdl.handle.net/10138/235191

Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma

Autor: Saukkonen, Kapo, Hagström, Jaana, Mustonen, Harri, Lehtinen, Laura, Carpen, Olli, Andersson, Leif, Seppänen, Hanna, Haglund, Caj

Publikováno v: In Pancreatology June 2018 18(4) Supplement:S127-S127

Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma.

Autor: Saukkonen K; 1 Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; 2 Translational Cancer Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland., Hagström J; 2 Translational Cancer Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.; 3 Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Mustonen H; 1 Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Lehtinen L; 4 Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland., Carpen O; 3 Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; 4 Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland.; 5 Genome Scale Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland., Andersson LC; 3 Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Seppänen H; 1 Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Haglund C; 1 Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; 2 Translational Cancer Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.

Publikováno v: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2018 Mar; Vol. 40 (3), pp. 1010428318761494.